Hyperlipidemia and cardiovascular disease: Inflammation, dyslipidemia, and atherosclerosis

Current Opinion in Lipidology

Volumn 25, Issue 1, 2014, Pages 94-95

  Tietge, Uwe J F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE CITRATE LYASE; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; EDITORIAL; ENZYME INHIBITION; EXERCISE; FATTY ACID SYNTHESIS; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; CLINICAL TRIALS AS TOPIC; EXERCISE; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; OXIDATIVE STRESS;

EID: 84893020943     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000051     Document Type: Editorial

References (9)

1. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451:904-913
2. Varbo A, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013; 128:1298-1309
3. Rosenson RS, Hurt-Camejo E. Phospholipase A2 enzymes and the risk of atherosclerosis. Eur Heart J 2012; 33:2899-2909
4. Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A2-IIA and cardiovascular disease: A Mendelian randomization study. J Am Coll Cardiol 2013; 62:1966-1976
5. Hurt-Camejo E, Gautier T, Rosengren B, et al. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice. Arterioscler Thromb Vasc Biol 2013; 33:2707-2714
6. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 2008; 134:405-415
7. Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-Activated protein kinase in patients with hypercholesterolemia: Results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62:1154-1162
8. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013; 62:709-714
9. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106:8665-8670